



Vaccines, a healthy future

Program Agenda

Developing Countries Vaccine Manufacturers' Network

21st Annual General Meeting

3rd to 5th November 2020

Virtual meeting

* Schedule shown in CET time

3rd November

11am: Members meeting to discuss common issues.

Potential discussion topic: framework for sustainable supply

DRAFT NOT FOR DISTRIBUTION

DAY 1 –Tuesday, November 3rd

11:00- 11 :15	General assembly (Private meeting) Opening Address <i>S. Prasad</i> (President, DCVMN) Welcome 10 min	Open to everyone Networking space Partners resources and videos
11:15 - 11:35	Annual Report approval and report of activities 2020: secretariat 10 min Budget 2021 for approval: treasurer 10 min	
11:35 - 12:30	Strategic presentations by EC members	
12:30 - 14:00	Partners Forum Chair: <i>T. Prusik</i> Co-Chair: <i>T. Chin Bin</i> Co-Chair: <i>M. Lundgren</i> Moderator: <i>B. Hayman</i>	
12:30 – 12:45	Update on NEW VVMs in support of SARS-COV2 vaccine delivery (including those in ultra-cold chain storage) <i>T. Prusik</i> , Zebra Temptime	
12:45 – 13:00	Re-imaging vaccine manufacturing: Shifting the paradigm of vaccine process development and manufacturing post pandemic <i>J. Cheng</i> , Merck	
13:00 – 13:10	Production of viral vector vaccines for pandemic use <i>M. Lundgren</i> , Cytiva	
13:15 – 13:25	Aseptic Blow-Fill-Seal fill/finish technology and vaccines <i>T. Kram</i> , Rommelag	
13:25 – 13:30	Tofflon: Best practices for human vaccines manufacturing <i>T. Xu</i> , Tofflon	
13:35 – 13:40	Biozeen approach to steering Covid - 19 manufacturing dynamics <i>V. Joseph</i> , Biozeen	
13:40 -13:45	Considerations for adapting existing facilities to changing vaccine development demands <i>A. Daruvala</i> , Bioengineering	
13:45 – 13:50	Vaccine production with GEA pharma separators <i>M. Kühberger</i> , GEA	
13:50 – 14:00	Q&A	

DAY 2–Wednesday, November 4th

Vaccines, a healthy future	
	Chair: <i>S. Prasad</i> Co-chair: <i>L. Yang</i> Moderator: <i>M. Dennehy</i>
11:00 – 11:10	Opening: DCVMN Presidential address <i>S. Prasad, DCVMN President</i>
11:10 -11:15	The COVID-19 pandemic outlook (pre-recorded video) <i>T. Ghebreyesus, WHO</i>
11:15 – 11:30	ACT – Accelerator: The plan, progress & challenges <i>B. Aylward, WHO</i>
11:30–11:45	The COVAX Facility and the AMC <i>S. Berkley, Gavi</i>
11:45 - 12:00	Covid vaccines’ development and manufacturing <i>R. Hatchett, CEPI</i>
12:00 – 12:15	UNICEF procurement for Covid-19 vaccines <i>E. Kadilli, UNICEF</i>
12:15 – 12:30	VIPS: Next steps post prioritisation <i>M. Menozzi, GAVI & B. Giesing, WHO</i>
12:30 – 12:45	Imperial Future Vaccine Manufacturing Research Hub <i>B. Pierce, FVMR Hub</i>
12:45 – 13.00	MANAGE COV <i>A. Bernaert, WEF</i>
13:00 – 13:15	Data, Decision-making and Development <i>C. Mehta & B. Evans, CHAI</i>
13:15 – 13:30	PATH moving public health (pre-recorded video) <i>N. Gilbert, PATH</i>
13:30 – 13:45	The PAHO COVID-19 Response <i>J. Barbosa, PAHO</i>
13:45 – 14:00	Pandemic response: The critical role of DCVMs <i>A. Zaidi, BMGF</i>

DAY 3– Thursday, November 5th

	Chair: <i>R. Park</i> Co-chair: <i>F. Lobos</i> Moderator: <i>S. Jarrett</i>
11:00 - 11:15	IVI collaborations to develop new vaccines <i>J. Kim, IVI</i>
11:15 – 11:30	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine <i>S. Gilbert, Jenner Institute, Oxford University</i>
11:30 – 11:45	Regulatory challenges for COVID-19 vaccine Development <i>M. Saville, CEPI</i>
11:45- 12:00	COVID-19 Vaccine: Clinical Trials and Tribulations <i>R. Ella, Bharat Biotech</i>
12:00 – 12:15	Cross-continent Vaccine Collaboration Against COVID-19 <i>W. Meng, Sinovac</i>
12:15 - 12:30	COVID-19 vaccine activities <i>M. Reers, Biological E</i>
12:30 – 12:45	Manufacture of Covid-19 Vaccine <i>M. Joshi & N. Tamhankar, Serum Institute of India</i>
12:45 – 13:00	Developments in Supply chain <i>T. Wilmansyah, Biofarma</i>
13:00 – 13:15	COVID-19 vaccine R&D and CNBG's Product Portfolio <i>L. Meng, CNBG</i>
13:15 – 13:30	Regulatory alignment and authorization of vaccines under EUL/PQ <i>C. Rodriguez, WHO</i>
13:30 – 13:45	Harmonization of regulatory approaches in African countries <i>S. Azatyan, WHO</i>
13:45 – 14:00	3Rs Improvement of legacy vaccines release testing. The case of the Pertussis Serological Potency Test <i>C. Von Hunolstein, Istituto Superiore di Sanità, Italia</i>
14:00 – 14:15	Closing remarks <i>P. Tippoo, DCVMN Vice-president</i>
